NCT06592586View on ClinicalTrials.gov

A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

338

Participants

Timeline

Start Date

March 7, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2029

Conditions
Streptococcus Agalactiae InfectionNeonatal SepsisPneumoniaMeningitisNeonatal InfectionGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfections
Interventions
BIOLOGICAL

GBS-NN/NN2 vaccine

0.5 mL (50 μg GBS-NN +50 μg GBS-NN2 adsorbed to 0.5 mg aluminium as Alhydrogel®)

Trial Locations (5)

2001

RECRUITING

Wits Reproductive Health and HIV Institute (Wits RHI), Johannesburg

6000

RECRUITING

Sygehus Lillebælt - Kolding Sygehus, Kolding

8200

RECRUITING

Aarhus Universitetshospital, Aarhus N

0204

RECRUITING

Sefako Makgatho Health Sciences University, Medunsa Clinical Research Unit (MeCRU), Ga-Rankuwa

0152

RECRUITING

Setshaba Research Centre, Pretoria

Sponsors

Lead Sponsor

Minervax ApS
All Listed Sponsors
lead

Minervax ApS

OTHER

NCT06592586 - A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women | Biotech Hunter | Biotech Hunter